Add office photos
Employer?
Claim Account for FREE
Biocon Limited
3.9
based on 1.9k Reviews
Company Overview
Associated Companies
Company Locations
Working at Biocon Limited
Company Summary
We are a global biopharmaceutical company changing patients’ lives in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases.
Overall Rating
3.9/5
based on 1.9k reviews
On-Par with
industry average
Highly rated for
Job security, Work-life balance
Critically rated for
Promotions
Work Policy
Work from office
83% employees reported
Monday to Saturday
42% employees reported
Flexible timing
81% employees reported
No travel
56% employees reported
View detailed work policy
Top Employees Benefits
Office cab/shuttle
2 employees reported
Child care facility
2 employees reported
Office gym
2 employees reported
Cafeteria
2 employees reported
View all benefits
Rate your company
🤫 100% anonymous
How was your last interview experience?
Share interview
About Biocon Limited
Founded in1978 (47 yrs old)
India Employee Count1k-5k
Global Employee Count5k-10k
India HeadquartersBangalore Rural, Karnataka, India
Office Locations
--
Websitebiocon.com
Primary Industry
Other Industries
Are you managing Biocon Limited's employer brand? To edit company information,
claim this page for free
We are a global biopharmaceutical company which believes that everyone has a right to affordable quality medicines.
Powered by advanced therapy platforms, our 13,500+ employees blend heart, science and creativity to make better healthcare solutions.
Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.
We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. By making medicines more easily accessible for patients across the globe, we’re working towards achieving health equity.
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines.
We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Mission: To be an integrated biotechnology enterprise of global distinction. Essential to this mission is excellence in:
Intellectual asset creation through discovery, research and development
State-of-the-art manufacturing capabilities
Internationally benchmarked quality and regulatory systems
New medical insight through disease-specific clinical research
Customer relationship through outstanding products and services
Human resource development through training, mentoring and empowering
Management of research and business partnerships
Vision: To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe.
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Biocon
Biocon Research
4.2
• 61 reviews
Biocon Foundation
2.0
• 11 reviews
Biocon Limited Ratings
based on 1.9k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
795
4
604
3
277
2
107
1
122
Category Ratings
3.8
Job security
3.8
Work-life balance
3.7
Company culture
3.7
Skill development
3.6
Salary
3.5
Work satisfaction
3.1
Promotions
Biocon Limited is rated 3.9 out of 5 stars on AmbitionBox, based on 1.9k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Biocon Limited
based on 1.8k reviews
3.9
Rated by 282 Women
Rated 3.7 for Work-life balance and 3.7 for Job security
3.9
Rated by 1.5k Men
Rated 3.8 for Work-life balance and 3.8 for Company culture
Work Policy at Biocon Limited
based on 262 reviews in last 6 months
Work from office
83%
Hybrid
14%
Permanent work from home
3%
Biocon Limited Reviews
Top mentions in Biocon Limited Reviews
+ 5 more
Saint-Gobain
We thank our employees for rating us 
4/5 on AmbitionBox
4/5 on AmbitionBoxJoin a company where our employee's ratings speak volumes.
Compare Biocon Limited with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 1.9k reviews | 4.0/5 based on 5.8k reviews  | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Work-life balance Job security | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Promotions |  No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 83% employees reported | Work from office 82% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 282 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 1.5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.8 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Biocon Limited Salaries
Biocon Limited salaries have received with an average score of 3.6 out of 5 by 1.9k employees.
Junior Executive
(538 salaries)
Unlock
₹2.3 L/yr - ₹5.1 L/yr
Deputy Manager
(395 salaries)
Unlock
₹7 L/yr - ₹18 L/yr
Executive Production
(268 salaries)
Unlock
₹3 L/yr - ₹6.1 L/yr
Senior Scientist
(229 salaries)
Unlock
₹4.7 L/yr - ₹11.5 L/yr
Principal Scientist
(162 salaries)
Unlock
₹6 L/yr - ₹15.1 L/yr
Executive Engineer
(108 salaries)
Unlock
₹3.2 L/yr - ₹6.3 L/yr
Scientist
(108 salaries)
Unlock
₹2.8 L/yr - ₹6.5 L/yr
Territory Business Manager
(88 salaries)
Unlock
₹3.4 L/yr - ₹7.6 L/yr
QC Executive
(84 salaries)
Unlock
₹2.7 L/yr - ₹5.3 L/yr
Associate Director
(62 salaries)
Unlock
₹25 L/yr - ₹47 L/yr
Biocon Limited Interview Questions
Interview questions by designation
Top Biocon Limited interview questions and answers
Get interview-ready with top interview questions
Biocon Limited Jobs
Popular Skills Biocon Limited Hires for
Current Openings
Biocon Limited News
View all
Stock Market Today: All You Need To Know Going Into Trade On Feb. 25
- Indian benchmark indices closed lower on Monday, with Nifty at 22,553.35 and Sensex at 74,454.41, marking their longest losing streak since November 1996.
- Foreign portfolio investors sold Indian equities worth Rs 6,286.7 crore while domestic institutional investors bought equities worth Rs 5,185.7 crore.
- The Indian rupee ended flat at 86.71 per dollar after erasing early gains, following a slump in US business activity.
- Stocks to watch include ONGC, NTPC, Firstsource Solutions, and Biocon, among others, with updates on their investments and developments.
- Trading tweaks included price band changes, stocks trading ex-dividend, and movements in the ASM framework for various companies.
- In F&O cues, Nifty futures were down, open interest decreased, and key levels for Options Feb. 27 Expiry were at 23,000 and 22,500.
- Bulk deals saw Quality Power Electrical Equipments and Pentateam Inventure Capital involved in significant share transactions.
- Insider trades included acquisitions by promoters in NCL Industries, Alembic Pharma, and KCP, among others.
- Scheduled meetings between companies and investors/analysts for Fino Payments Bank, Axis Bank, and others were announced.
- The Indian rupee finished flat against the US dollar at 86.71, witnessing pressure due to weakening US business activity.
Bloomberg Quint | 25 Feb, 2025
Biocon Board Okays Issuing Of Commercial Papers Worth Rs 570 Crore
- Biocon Ltd. plans to raise Rs 570 crore through the issuance of commercial papers on a private placement basis.
- Commercial papers are short-term, unsecured debt obligations issued as an alternative to costlier funding methods.
- Biocon has also achieved an improvement in its Environmental, Social, and Governance (ESG) scores, with an S&P Global ESG score of 69 in 2024.
- This places Biocon in the 98th percentile among its global biotechnology industry peers.
Bloomberg Quint | 27 Jan, 2025
"Tragic to See This Happen,” Biocon Chief Regrets as Fire at Bengaluru’s Startup Hub Causes Loss of Rs 150 Cr
- A massive fire at the Bangalore Bioinnovation Centre (BBC) in Electronics City caused a loss of around Rs 150 crore.
- Karnataka IT-BT minister Priyank Kharge expressed commitment to helping affected startups rebuild.
- Biocon Limited Executive Chairperson Kiran Mazumdar-Shaw expressed regret and emphasized the need for fire preparedness.
- Startups at the BBC have incurred losses ranging from Rs 80 crore to Rs 110 crore, with damage to BBC properties around Rs 42 crore.
Startup Pedia | 16 Jan, 2025
F&O Query: Should you hold Biocon put option?
- Biocon stock has been moving in a sideways trend since July last year, with a resistance at ₹385-₹395.
- The stock is currently trading near the upper end of the range and could see a drop to ₹325, with support at ₹350.
- Holding the 320-put option is recommended as the stock may decline soon, but a drop below ₹320 is less likely.
- If the stock declines to ₹350-₹335 in about a week, the 320-put option's premium could rise to ₹1-₹3 with a target of ₹2.
HinduBusinessLine | 9 Jan, 2025
The Fifth Episode of Crafting Bharat: Deep Tech with Fermbox Bio
- India's bioeconomy has witnessed a surge from US$10 billion in 2014 to over US$130 billion in 2024.
- Fermbox Bio is pioneering precision fermentation as India's tech ecosystem flourishes.
- Fermbox Bio is building a million-litre fermentation facility in Thailand in partnership with BBGI.
- Fermbox Bio's goal is to disrupt global fermentation by focusing on collaboration and scalability.
- Nithish Kumar from Speciale Invest interviews Fermbox Bio's Subramani Ramachandrappa in this episode.
- They discuss the complexities of the biotech sector and what precision fermentation means.
- Fermbox Bio makes enzymes free of animal derivatives to make vaccines safer.
- Subramani Ramachandrappa left Biocon to start his entrepreneurial journey with Richcore.
- Richcore was later acquired by Laurus Labs, paving the way for the establishment of Fermbox Bio.
- Subramani Ramachandrappa believes biotech's future will lie in openness and partnerships.
VIE Stories | 4 Jan, 2025
Stock Market Live Updates 3 January 2025: Stock to buy today: Mahindra & Mahindra (₹3,210) BUY
- Benchmark indices rose over 1.8 per cent on Thursday, led by strong buying in index heavyweights.
- The Sensex settled at 79,943, up 1,436 points or 1.83 per cent from its previous close.
- The Nifty50 ended at 24,188, up 445 points or 1.88 per cent.
- Smallcap 100 Index posted a more modest gain of 0.64 per cent.
- Strong buying was seen in heavyweights especially auto, NBFCs and IT stocks, driven by optimism about upcoming quarterly earnings.
- DMart added 10 stores during the quarter, taking the count to 387 stores.
- Shaily Innovations FZCO, in Dubai, UAE, will be engaged in contracts involving design and development of drug delivery devices.
- NHPC received Rs 250 crore as the second installment of gross payment under a mega insurance policy.
- Biocon receives NMPA approval for Tacrolimus capsules in China.
- Deepak Builders saw CRISIL upgrading the company's long term rating to BBB+.
HinduBusinessLine | 3 Jan, 2025
Stocks that will see action today: January 3
- SEBI dismisses settlement applications filed by Zee Entertainment and Punit Goenka, referring the matter for further investigation.
- Biocon Pharma receives approval for Tacrolimus capsule from the NMPA, China.
- NHPC receives a payment of ₹250 crore under a mega insurance policy for loss caused by a flash flood.
- V2 Retail reports a 58.1% increase in revenue from operations for the December quarter.
HinduBusinessLine | 3 Jan, 2025
Biocon Sells Syngene’s Shares Worth Rs 686 Crore
- Biocon Ltd. sold Syngene shares worth Rs 686 crore via block deals on the BSE, reducing its stake while maintaining majority ownership at 52.46%.
- The transaction took place in the open market and none of the buyers belong to the promoter, promoter group, or group companies.
- Biocon's subsidiary Biocon Biologics Ltd. received US FDA approval for Yesintek, a biosimilar for Johnson & Johnson's reference product, Stelara.
- For the second quarter of fiscal 2025, Biocon's consolidated net profit fell 84.3% to Rs 27.1 crore compared to the year-ago period.
Bloomberg Quint | 10 Dec, 2024
AdvantageClub.ai bags $4M in funding led by Axilor Ventures
- AdvantageClub.ai, a company specializing in employee engagement solutions, has raised $4 million in a funding round led by Axilor Ventures.
- The funding round also saw participation from AFG Ventures, Prasanna Sarkar, Bytez Ventures, and existing ventures, bringing the total funding raised by AdvantageClub.ai to $11 million.
- The company plans to utilize the funding to expand into the US and Asia, strengthen its position in rewards and recognition, and develop wellness programs.
- AdvantageClub.ai, founded in 2016, provides its services to clients such as Tech Mahindra, HCL, Concentrix, Hexaware, Biocon, Tata Steel, and Air India.
Yourstory | 2 Dec, 2024
Biocon Biologics Receives US FDA Nod For Yesintek, A Biosimilar to J&J's Stelara
- Biocon Biologics has received FDA approval for Yesintek, a biosimilar for Johnson & Johnson's Stelara.
- Yesintek, a monoclonal antibody, will treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
- This approval will provide affordable access to high-quality biosimilars for millions of patients worldwide.
- Biocon Biologics is set to commercialize Yesintek in the United States by February 22, 2025.
Bloomberg Quint | 1 Dec, 2024
Powered by
Biocon Limited Offices
Compare Biocon Limited with
Torrent Pharmaceuticals
3.9
Lupin
4.2
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Piramal Group
3.9
Thermo Fisher Scientific
3.9
Biocon Biologics
3.6
Panacea Biotec
3.7
LifeCell International
3.4
Praj Industries
4.1
Serum Institute of India
4.1
Bharat Biotech International
3.1
Transasia Bio-Medicals
3.2
Indian Immunologicals
4.1
Jubilant Biosys
3.8
Avantor
3.5
Novozymes South Asia
4.1
JK Agri Genetics
3.9
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to Biocon Limited
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Piramal Group
Pharma
3.9
• 1.1k reviews
Thermo Fisher Scientific
Biotech & Life sciences, Internet, Analytics & KPO, Biotechnology, Pharma
3.9
• 826 reviews
Biocon Biologics
Biotechnology
3.6
• 814 reviews
Biocon Limited FAQs
When was Biocon Limited founded?
Biocon Limited was founded in 1978. The company has been operating for 47 years primarily in the Biotechnology sector.
Where is the Biocon Limited headquarters located?
Biocon Limited is headquartered in Bangalore Rural, Karnataka.
How many employees does Biocon Limited have in India?
Biocon Limited currently has more than 3,600+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in Biocon Limited based on the number of reviews submitted on AmbitionBox.
Does Biocon Limited have good work-life balance?
Biocon Limited has a Work-Life Balance Rating of 3.8 out of 5 based on 1,900+ employee reviews on AmbitionBox. 73% employees rated Biocon Limited 4 or above, while 27% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Biocon Limited work-life balance reviews for more details
Is Biocon Limited good for career growth?
Career growth at Biocon Limited is rated as moderate, with a promotions and appraisal rating of 3.1. 27% employees rated Biocon Limited 3 or below, while 73% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Biocon Limited promotions/appraisals reviews for more detailed insights.
What are the pros and cons of working in Biocon Limited?
Working at Biocon Limited comes with several advantages and disadvantages. It is highly rated for job security and work life balance. However, it is poorly rated for promotions / appraisal, based on 1,900+ employee reviews on AmbitionBox.
Recently Viewed
COMPANY BENEFITS
Sabre
No Benefits
COMPANY BENEFITS
Biocon Limited
No Benefits
SALARIES
Sabre
No Salaries
REVIEWS
Fujitsu
No Reviews
LIST OF COMPANIES
Sabre
Overview
REVIEWS
A2Z Events
No Reviews
JOBS
Sabre
No Jobs
JOBS
Fujitsu
No Jobs
PHOTOS
Fujitsu
No Photos
REVIEWS
Sabre
No Reviews
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
